Smiths Group PLC
02 August 2005
News Release
London, Tuesday 2 August 2005
For immediate release
Year-End Trading Statement
Smiths Group will announce its preliminary results for the year ended 31 July,
2005, on Thursday, 22 September. At the start of its close period the company
is issuing the following trading update, based on estimates and subject to
adjustment.
As forecast at the time of the interim results, the strong sales and profit
growth momentum seen in the first six months has been sustained through the full
year.
Sales have increased by 11%, and headline* operating profit is expected to be
approximately 16% ahead of the prior year, reflecting a half percent net margin
improvement. All four divisions are expected to have achieved double-digit
improvements in operating profit. This divisional performance has been
achieved despite a currency translation impact of approximately £11m caused
primarily by the weaker dollar, and a higher level of investment in R&D. In
addition to good organic growth, recent acquisitions have made a valuable
contribution, and their integration is proceeding well.
The company expects to report an increase in pre-tax profit of around 17%,
resulting in headline* earnings per share in line with the market consensus of
54p, compared with 45.9p in 2004.
Net debt at the year-end will be in the region of £950m, principally due to
recent acquisitions. Increased capital expenditure and a higher level of
working capital is expected to result in a lower than normal conversion of
operating profit into cash. Exceptional charges are likely to be in the region
of £50m, comprising the second year of the restructuring programme commenced in
2004, the initial phase of Medex integration and the settlement of the
litigation involving the Cozmo diabetes pump.
Following publication of the 2005 Accounts, the results will be restated under
International Financial Reporting Standards (IFRS), to allow easier comparison
with the years ahead. As indicated in July, had IFRS been adopted for 2005, the
effect would have been to increase pre-tax profit by about 6% compared with the
current UK GAAP basis. For the new financial year to July 2006, the company
will publish its results using IFRS.
The company is confident of the prospects for growth in 2006. In the sectors
important to Smiths, the market outlook remains positive. Additionally, recent
acquisitions are yielding synergy benefits, increased investment in product
development is paying off, and the continuous productivity drive will enhance
profitability.
- o -
* 'Headline' profits and earnings per share are before exceptional charges and
amortisation of goodwill.
The company will hold a conference call for analysts and investors at 2.00pm
today, London time. The call can be accessed on:
UK toll free number: 0800 018 0764 US toll free number: 1-877 951 7311
Passcode: Year-End Leader: Russell Plumley
From 4.00pm, a recording of the call can be heard on:
UK toll free number: 0800 376 9053 US toll free number: 1-866 851 5334
Media: Investors:
Chris Fox Russell Plumley
+44 (0) 20 8457 8403 +44 (0) 20 8457 8203
chris.fox@smiths-group.com russell.plumley@smiths-group.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.